AbdullGaffar Badr
Dubai Hospital, Dubai, UAE.
Diagn Cytopathol. 2025 Nov;53(11):555-567. doi: 10.1002/dc.70013. Epub 2025 Aug 21.
Compared to myelomatous effusions, there is a lack of studies that specifically address hematolymphoid plasmacytic effusions (HPEs). We conducted a retrospective review study over 15 years to investigate the prevalence, cytologic patterns, potential interpretation pitfalls, and clinical associations of HPEs. Serous effusion fluids in which plasmacytoid and plasma cells represented more than 10% of effusion cells were classified as HPEs. We extracted relevant clinical, laboratory, and follow-up data for each patient. We found six patients [age range: 60-88, average age: 73, male to female ratio 1:1] with HPEs that constituted 0.2% of serous effusions. Relevant clinical history prompted us to consider HPEs and include plasma cell immunomarkers in cellblock sections. Light chain-restricted plasmacytic cellular infiltrates confirmed the cytologic diagnosis in the absence of fluid flow cytometry. We have recognized three cytomorphologic patterns: pure plasmacytic infiltrates, lymphoplasmacytic infiltrates, and plasma cells intermixed with other cellular constituents. Four patients had multiple myeloma (two patients with pure high-grade large pleomorphic myeloma cells, two patients with mature plasma cells intermixed with inflammatory cells), one patient had marginal zone lymphoma, and another patient had lymphoplasmacytic lymphoma. The patients had similar clinical features with even kappa (3 cases) and lambda (3 cases) light chain distribution. HPEs are uncommon malignant effusions that occur in elderly patients with multiple myeloma and low-grade B-cell lymphomas. High-grade myeloma cells can be confused with hematolymphoid and non-hematolymphoid malignancies, whereas mature plasma cells in multiple myeloma and low-grade lymphomas can be misinterpreted as reactive plasmacytosis. Cellblock immunocytochemistry is a valuable diagnostic tool.
与骨髓瘤性积液相比,专门针对血液淋巴样浆细胞性积液(HPEs)的研究较少。我们进行了一项为期15年的回顾性研究,以调查HPEs的患病率、细胞学模式、潜在的解读陷阱以及临床关联。浆细胞样细胞和浆细胞占积液细胞10%以上的浆液性积液被归类为HPEs。我们提取了每位患者的相关临床、实验室和随访数据。我们发现6例患者[年龄范围:60 - 88岁,平均年龄:73岁,男女比例1:1]患有HPEs,占浆液性积液的0.2%。相关临床病史促使我们考虑HPEs,并在细胞块切片中纳入浆细胞免疫标志物。在没有流式细胞术检测积液的情况下,轻链受限的浆细胞浸润证实了细胞学诊断。我们识别出三种细胞形态学模式:单纯浆细胞浸润、淋巴浆细胞浸润以及浆细胞与其他细胞成分混合。4例患者患有多发性骨髓瘤(2例为单纯高级别大的多形性骨髓瘤细胞,2例为成熟浆细胞与炎性细胞混合),1例患者患有边缘区淋巴瘤,另1例患者患有淋巴浆细胞淋巴瘤。这些患者具有相似的临床特征,κ链(3例)和λ链(3例)分布均衡。HPEs是罕见的恶性积液,发生于患有多发性骨髓瘤和低级别B细胞淋巴瘤的老年患者中。高级别骨髓瘤细胞可能与血液淋巴样和非血液淋巴样恶性肿瘤混淆,而多发性骨髓瘤和低级别淋巴瘤中的成熟浆细胞可能被误诊为反应性浆细胞增多症。细胞块免疫细胞化学是一种有价值的诊断工具。